Abeona Therapeutics Inc. (ABEO)
| Market Cap | 138.30M -48.3% |
| Revenue (ttm) | 39.01M +9,652.8% |
| Net Income | -62.53M |
| EPS | -1.13 |
| Shares Out | 57.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,176,469 |
| Open | 2.325 |
| Previous Close | 2.290 |
| Day's Range | 2.090 - 2.435 |
| 52-Week Range | 2.090 - 7.650 |
| Beta | 1.48 |
| Analysts | Strong Buy |
| Price Target | 15.56 (+542.98%) |
| Earnings Date | Nov 9, 2026 |
About ABEO
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platfor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ABEO stock is "Strong Buy." The 12-month stock price target is $15.56, which is an increase of 542.98% from the latest price.
News
Abeona Therapeutics price target lowered to $18 from $30 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Abeona Therapeutics (ABEO) to $18 from $30 and keeps a Buy rating on the shares following the Q3 report. The firm says…
Abeona Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026
ZEVASKYN reached 15 treated patients by Q3 2026, with four of eight activated centers having treated patients and all eight targeted by mid-2027. ABO-801 adds an EoE Phase III program, with a redesigned symptom endpoint and backloaded acquisition economics.
Abeona Therapeutics price target lowered to $7.50 from $17 at Roth Capital
Roth Capital lowered the firm’s price target on Abeona Therapeutics (ABEO) to $7.50 from $17 and keeps a Buy rating on the shares after its Q3 results. The stock fell…
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
CLEVELAND, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November 2...
Abeona Therapeutics Earnings Call Transcript: Q3 2026
ZEVASKYN revenue rose 18% QoQ to $13.5M as treatment experience expanded across eight centers. ABO-801 adds a Phase III EoE candidate, with a ~400-patient trial planned to start in mid-2027.
Abeona Therapeutics Earnings release: Q3 2026
Abeona Therapeutics released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Abeona Therapeutics Slides: Q3 2026
Abeona Therapeutics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 9, 2026.
Abeona Therapeutics Quarterly report: Q3 2026
Abeona Therapeutics has published its Q3 2026 quarterly earnings report on November 9, 2026.
Abeona Therapeutics Slides: Clinical Development History presentation
Abeona Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 9, 2026.
Abeona Therapeutics acquires APT-1011 from Ellodi Pharmaceuticals
Abeona Therapeutics (ABEO) announced the acquisition of APT-1011 (now ABO-801), a product candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals, and entered into a securities purchase ag...
Abeona Therapeutics enters $30M private placement
Under the terms of the asset purchase agreement, Abeona agreed to issue Ellodi $20 million of Abeona common stock, with no upfront cash consideration. Ellodi is also eligible to receive…
Abeona Therapeutics reports Q3 EPS (8c), consensus (17c)
Reports Q3 revenue $13.49M, consensus $14.82M. “Maximizing the opportunity for ZEVASKYN remains our number one priority. During the third quarter, we continued to build the commercial foundation for Z...
Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress
– Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2 – – 15 ZEVASKYN treatments completed since launch, including six during Q3 – - QTC network expanded to eight sites; four centers...
Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement
- Adds a once-daily, oral therapy candidate for eosinophilic esophagitis with FDA Orphan Drug and Fast Track Designations –
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awar...
Abeona Therapeutics Slides: Corporate presentation
Abeona Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 22, 2026.
Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111
Abeona Therapeutics (ABEO) “congratulated” Ultragenyx Pharmaceutical (RARE) on the U.S. Food and Drug Administration, FDA, approval of FAYUVI, also known as UX111, a gene therapy for the treatment of ...
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona's foundational R&D and clinical development efforts -
Abeona Therapeutics price target raised to $30 from $28 at Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Abeona Therapeutics (ABEO) to $30 from $28 and keeps an Overweight rating on the shares. Abeona’s partner Ultragenyx (RARE)…
Abeona Therapeutics initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Abeona Therapeutics (ABEO) with a Buy rating and $17 price target The firm cites Zevaskyn’s “durable” profile targeting recessive dystrophic epidermolysis bullosa fo...
Abeona Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted the commercial launch of a novel gene therapy for a severe genetic skin disorder, emphasizing its unique durability, operational challenges, and expanding treatment center network. Key metrics for future growth include patient treatment cadence, site activation, and manufacturing scalability.
Abeona activates UF Health as qualified treatment center for Zevaskyn
Abeona Therapeutics (ABEO) announced the activation of University of Florida Health in Gainesville, Florida, as the eighth qualified treatment center, or QTC, for the administration of Zevaskyn gene-m...
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet ne...
Abeona Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Strong commercial momentum for ZEVASKYN is supported by expanding treatment centers, robust payer coverage, and durable clinical outcomes. Pipeline progress includes key partnerships and a new prostate cancer asset, with multiple inflection points expected in the next year.
Abeona Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
ZEVASKYN's launch is progressing with expanding access, strong payer coverage, and positive early patient outcomes, while manufacturing and site capacity are scaling to meet demand. The pipeline and partnered programs offer additional revenue potential, and foundational work in 2024 is expected to drive significant growth by 2026–2027.